Publicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (225)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

  2. Diagnóstico y tratamiento de los trastornos de la presión intracraneal: Documento de consenso del Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología

    Neurologia

  3. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  4. Health service and psychotropic medication use for mental health conditions among healthcare workers active during the Spain Covid-19 Pandemic – A prospective cohort study using web-based surveys.

    Psychiatry Research, Vol. 334

  5. Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register

    RMD open, Vol. 10, Núm. 1

  6. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588

  7. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

  8. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

    JAMA network open, Vol. 7, Núm. 4, pp. e247811

  9. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

  10. Surgery for inflammatory bowel disease in Spain: How are we doing? Initial results of a nationwide prospective registry

    Cirugia Espanola

  11. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

  12. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology

  13. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5